ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

FTI Consulting Adds Two Senior Life Sciences Professionals to Health Solutions Practice

WASHINGTON, April 24, 2023 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Anthony Gotzis as a Senior Managing Director and Jacinthe Guindon as a Managing Director in the Life Sciences offering within the firm’s Health Solutions practice.

“Our clients in the life sciences industry look to us to solve their biggest business challenges,” said Charles Overstreet, Global Leader of the Health Solutions practice at FTI Consulting. “Anthony and Jacinthe, who have more than 60 years of combined experience in the life sciences industry, will bring real-world knowledge and innovative ideas to our clients who are navigating an increasingly complex environment.”

Mr. Gotzis, who is based in Philadelphia, brings to FTI Consulting nearly 30 years of experience in the life sciences industry as a trusted advisor, having worked with nearly all sectors of the industry. His experience includes implementing large transformation initiatives to achieve operational efficiencies and risk mitigation. In his role at FTI Consulting, Mr. Gotzis will lead the Life Sciences R&D and Quality capability team within the Life Sciences offering.

Commenting on his appointment, Mr. Gotzis said, “Life sciences companies are under enormous pressure to bring drugs and devices to market faster, with fewer resources and in a manner compliant with various health authority regulations. I look forward to working with the deep pool of talented professionals at FTI Consulting as we help clients address their most challenging operational, transformational and risk-based needs.”

Ms. Guindon, who is based in Toronto, joins FTI Consulting with more than 30 years of experience in all facets of clinical development that span pharmaceuticals, biopharmaceuticals and medical devices in the United States and Canada. She has overseen the development of many therapeutics, from early-stage to approval. Ms. Guindon also has led the strategic planning and management of clinical trials. In her role at FTI Consulting, she will focus on clinical development, clinical compliance and trial and portfolio management.

About the Life Sciences offering
FTI Consulting’s world-class capabilities across pharmaceuticals, biotechnology, medical device and diagnostics and the healthcare ecosystem enable the firm to assist clients in solving their most complex challenges, achieve their strategic and operational objectives and help shape the technology that will improve the lives of patients, customers and communities.

About FTI Consulting
FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 7,600 employees located in 31 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $3.03 billion in revenues during fiscal year 2022. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.

FTI Consulting, Inc.
555 12th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:
Matthew Bashalany
+1.617.897.1545
matthew.bashalany@fticonsulting.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.